切换至 "中华医学电子期刊资源库"

中华腔镜外科杂志(电子版) ›› 2023, Vol. 16 ›› Issue (01) : 38 -43. doi: 10.3877/cma.j.issn.1674-6899.2023.01.010

论著

腹腔镜肝切除术治疗合并血小板减少肝细胞癌患者的疗效和安全性
赵晓飞1, 邸亮1, 张健2, 栗光明1, 曾道炳1,()   
  1. 1. 100069 北京,首都医科大学附属北京佑安医院普通外科中心;100069 北京,首都医科大学肝癌临床诊疗及研究中心
    2. 250101 济南,山东省济南市第三人民医院肝胆外科
  • 收稿日期:2023-01-10 出版日期:2023-02-28
  • 通信作者: 曾道炳
  • 基金资助:
    首都医科附属北京佑安医院2021年度院内中青年人才孵育项目(青年创新类)(YNKTQN2021017)

Efficacy and safety of laparoscopic liver resection for hepatocellular carcinoma with thrombocytopenia

Xiaofei Zhao1, Liang Di1, Jian Zhang2, Guangming Li1, Daobing Zeng1,()   

  1. 1. Department of General Surgery Center, Capital Medical University Affiliated Youan Hospital, Beijing 100069, China; Clinical Center for Liver Cancer, Capital Medical University, Beijing 100069, China
    2. Department of Hepatobiliary Surgery, The Third Hospital of Jinan, Shandong Province, Jinan 250101, China
  • Received:2023-01-10 Published:2023-02-28
  • Corresponding author: Daobing Zeng
引用本文:

赵晓飞, 邸亮, 张健, 栗光明, 曾道炳. 腹腔镜肝切除术治疗合并血小板减少肝细胞癌患者的疗效和安全性[J/OL]. 中华腔镜外科杂志(电子版), 2023, 16(01): 38-43.

Xiaofei Zhao, Liang Di, Jian Zhang, Guangming Li, Daobing Zeng. Efficacy and safety of laparoscopic liver resection for hepatocellular carcinoma with thrombocytopenia[J/OL]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2023, 16(01): 38-43.

目的

探讨腹腔镜肝切除(laparoscopic liver resection,LLR)对合并血小板减少肝细胞癌患者的有效性及安全性。

方法

回顾性分析2020年4月至2022年11月首都医科大学附属北京佑安医院因肝细胞癌行LLR的141例患者临床资料,根据血小板计数(PLT)是否<100×109/L分为PLT减少组和PLT正常组,比较两组患者术中出血量、肝门阻断比例、肝门阻断时间、手术时间、术中输血量、术中是否放置引流管、术后并发症、住院时间等数据,探讨PLT水平对LLR出血量的影响和手术的安全性。

结果

141例患者完成LLR,术中均未输注红细胞悬液,PLT减少组和PLT正常组的中位出血量分别为100 mL和50 mL,两组间差异无统计学意义(P=0.111),两组间肝门阻断比例、肝门阻断时间、手术时间和术中输血浆量均差异无统计学意义,PLT减少组放置引流管的比例明显高于PLT正常组(94.29%比78.50%,P=0.040);PLT减少组与PLT正常组术后并发症发生率差异无统计学意义(20.00%比10.28%,P=0.149);两组术后中位住院时间分别为7 d和6 d,差异无统计学意义(P=0.062)。

结论

通过仔细解剖、适当地肝门阻断和低中心静脉压技术,对合并血小板减少的肝细胞癌患者实施LLR是安全、可行的,经验丰富的腹腔镜肝脏外科医师还可以做到无输血LLR。

Objective

To investigate the effect of laparoscopic liver resection(LLR) on intraoperative bleeding in hepatocellular carcinoma (HCC) patients with thrombocytopenia.

Methods

The clinical data of 141 patients who underwent LLR for HCC in Department of General Surgery Center, Capital Medical University Affiliated Youan Hospital from Apr.2020 to Nov. 2022 were analyzed retrospectively. According to the level of PLT, they were divided into PLT reduced group and PLT normal group. The blood loss during operation, the proportion of hepatic portal occlusion, the time of hepatic portal occlusion, the time of operation, the amount of blood transfusion during operation, whether drainage tubes were placed during operation, the complications after operation, and the length of hospital stay were compared between the two groups, To investigate the effect of PLT level on the amount of bleeding and the safety of LLR.

Results

141 patients completed LLR without intraoperative infusion of red blood cells. The median bleeding volume of PLT reduced group and PLT normal group was 100 mL and 50 mL respectively. There was no statistical difference between the two groups (P=0.111). There was no statistical difference between the two groups in the time of hepatic portal occlusion, the operation time, the proportion of hepatic portal occlusion, and the amount of intraoperative plasma transfusion. The proportion of drainage tubes of PLT reduced group was significantly higher than that of PLT normal group (94.29% vs 78.50%, P=0.040) There was no statistical difference in the incidence of postoperative complications between the PLT reduced group and the PLT normal group (20.00% vs 10.28%, P=0.149). The hospital stay after surgery was 7 days and 6 days respectively and there was no difference between the two groups (P=0.062).

Conclusions

LLR is safe and feasible for HCC patients with thrombocytopenia through careful anatomy, appropriate hepatic portal occlusion and low central venous pressure technology, and LLR without blood transfusion can also be performed by experienced hepatobiliary surgeon.

表1 两组合并血小板减少肝细胞癌患者基线资料比较
项目 血小板计数减少组(35例) 血小板计数正常组(107例) 统计值 P
年龄(岁,±s) 58.37±8.58 55.32±10.88 1.500 0.139
性别[例(%),男/女] 29(82.86)/6(17.14) 87(81.31)/20(18.69) 0.420 0.834
病因[例(%)]     6.900 0.431
HBV 26(74.29) 81(75.70)    
HCV 3(8.57) 6(5.61)    
酒精性肝病 1(2.86) 9(8.41)    
脂肪肝 1(2.86) 3(2.80)    
不明原因 3(8.57) 2(1.87)    
无肝病 1(2.86) 1(0.93)    
HBV+HCV 0(0.00) 1(0.93)    
HBV+酒精性 0(0.00) 3(2.80)    
Child-Pugh分级[例(%),A/B] 32(91.43)/3 (8.57) 103(96.26)/4(3.74) 1.310 0.364
WBC(×109/L) 3.23(2.90~4.34) 5.38(4.58~6.65) -6.691 <0.001
HGB(g/L) 139.00(133.00~148.00) 145.00(133.00~158.00) -1.584 0.113
PLT(×109/L) 71.00(58.00~86.00) 172.00(143.00~207.00) -8.864 <0.001
INR 1.14(1.11~1.23) 1.04(0.99~1.09) -6.145 <0.001
Tbil(μmol/L) 23.70(15.80~34.70) 18.10(13.00~23.10) -3.207 0.001
ALB(g/L) 39.50(37.60~42.40) 41.60(39.10~44.00) -2.301 0.021
AFP(ng/mL) 5.65(2.33~42.50) 8.03(3.37~184.00) -1.910 0.056
腹部手术史[例(%),有/无] 8(22.86)/27(77.14) 16(14.95)/91(85.05) 1.170 0.303
门静脉高压症[例(%),有/无] 33(94.29)/2(5.71) 64(59.81)/43(41.19) 31.02 <0.001
肝癌分期[例(%)]        
CNLC(Ⅰ/Ⅱ/Ⅲ/Ⅳ) 30(85.71)/4(11.43)/0(0.00)/1(2.86) 87(81.31)/12(11.21)/6(5.61)/2(1.87) 2.140 0.542
BCLC(0/A/B) 14(40.00)/20(57.14)/1(2.86) 29(27.10)/66(61.68)/12(11.21) 3.550 0.169
肿瘤位置[例(%)]     2.726 0.909
1(2.86) 2(1.87)    
3(8.57) 6(5.61)    
4(11.43) 12(11.21)    
3(8.57) 11(10.28)    
8(22.86) 29(27.10)    
6(17.14) 22(20.56)    
7(20.00) 12(11.21)    
3(8.57) 13(12.15)    
表2 两组合并血小板减少肝细胞癌患者术中资料比较
表3 两组合并血小板减少肝细胞癌患者术后资料比较
1
Abu Hilal M, Aldrighetti L, Dagher I,et al. The southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation[J]. Annals of surgery2018268(1):11-18.
2
Chao YJ, Wang CJ, Shan YS. Technical notes: a self-designed, simple, secure, and safe six-loop intracorporeal pringle's maneuver for laparoscopic liver resection[J]. Surgical endoscopy201226(9):2681-2686.
3
Heaney JP, Stanton WK, Halbert DS,et al. An improved technic for vascular isolation of the liver: experimental study and case reports[J]. Annals of surgery, 1966163(2):237-241.
4
Hendi M, Lv J, Cai XJ. Current status of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma: a systematic literature review[J]. Medicine2021100(50):27826.
5
Liu TS, Shen QH, Zhou XY,et al. Application of controlled low central venous pressure during hepatectomy: a systematic review and meta-analysis[J]. Journal of clinical anesthesia202175:110467.
6
O′Leary JG, Greenberg CS, Patton HM, et al.Aga clinical practice update: coagulation in cirrhosis[J]. Gastroenterology2019157(1):34-43.
7
Latorre R, Vaquero J, Rincon D, et al. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis[J]. Liver Int201636(2):232-239.
8
曾道炳,邸亮,高大明,等. 完全腹腔镜下肝尾状叶原发性肝癌切除术一例[J]. 中华肝胆外科杂志2016, 22(1): 32,61.
9
曾道炳,邸亮,丁兢,等. 腹腔镜解剖性肝左外叶切除的技术改进[J]. 肝胆胰外科杂志2018, 30(4):324-326.
10
刘荣,赵国栋. 肝左外叶切除"金标准"术式:腹腔镜肝左外叶切除术[J/CD]. 中华腔镜外科杂志(电子版), 20103(6):474-478.
11
余海波,彭亚南,董亚东,等. 加速康复外科在腹腔镜精准肝切除中的应用价值[J]. 中华普通外科杂志2018, 33(5): 401-404.
12
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志2022, 30(4): 367-388.
13
谢国伟,李嘉鑫,吴泓. 吲哚氰绿荧光显像导航技术在复发性肝癌腹腔镜再次肝切除中的应用[J/CD]. 中华肝脏外科手术学电子杂志2020, 9(2): 153 -157.
14
赵国栋,马奔,刘荣. 肝脏流域学说下的控血新理念:适时分合肝脏控血技术[J]. 中华医学杂志2021, 101(40): 3261-3265.
15
刘荣,赵国栋. 肝脏解剖:从尸体静态解剖学下的树干理论到临床潜能形态学下的流域学说[J/CD]. 中华腔镜外科杂志(电子版)201811(5):257-260.
16
Tripodi A, Chantarangkul V, Primignani M, et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma[J]. Internal and emergency medicine20127(2):139-144.
17
Pang Q, Zhang JY, Liu SS, et al. Adverse effects of platelets on post-hepatectomy outcomes in patients with hepatocellular carcinoma[J]. Journal of hepatology, 201664(2):518-519.
18
何国林,洪合,程远,等. 快速康复外科理念在腹腔镜肝切除术中的应用[J]. 中华普通外科杂志2018, 33(8): 635-637.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 马旦杰, 黄品同, 徐琛, 周芳芳, 潘敏强. 超声造影LI-RADS系统联合甲胎蛋白对有无高危因素背景人群肝细胞癌的诊断价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(03): 288-296.
[3] 谢江燕, 王亚菲, 贺芳. 妊娠合并血栓性血小板减少性紫癜2例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 556-563.
[4] 李敏, 杨世英, 高晓琴, 周丹, 唐筱, 张立婷. 维生素A与慢性肝病相关性研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 65-70.
[5] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[6] 胡森焱, 徐冬, 方健, 谢冬冬, 王财庆. ICG荧光显影Laennec膜入路腹腔镜解剖性肝切除的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 513-516.
[7] 张金华, 赵锁. 早期ICC腹腔镜肝切除术不同淋巴结清扫范围的近远期效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 578-581.
[8] 陆朝阳, 金也, 孙备. 腹腔镜解剖性肝切除的发展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 363-366.
[9] 刘炯, 彭乐, 马伟, 江斌. 鞘外解剖肝蒂技术治疗肝内胆管细胞癌的疗效评估[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 373-376.
[10] 宋华传, 季鹏, 姚焕章, 王永帅, 张珅瑜, 宋瑞鹏, 王继洲. 腹腔镜肝切除术联合微波消融治疗多发性结直肠癌肝转移[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(04): 222-226.
[11] 王向丽, 吴涛, 毛东锋, 刘恒, 刘文慧, 周芮, 田红娟. 异基因造血干细胞移植治疗ANKRD26相关性血小板减少症1例并文献复习[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 236-238.
[12] 张龙, 孙善柯, 徐伟, 李文柱, 李俊达, 池涌泉, 何广胜, 成峰, 王学浩, 饶建华. 腹腔镜脾切除治疗血液系统疾病的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 870-875.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陆知非, 华永飞, 姜哲康, 高过, 江寅, 王高卿. 初始不可切除肝癌转化治疗的影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 268-274.
[15] 倪管崟, 缪小赟, 丁家安, 田鹏程, 倪才方. 锥形束计算机断层扫描在肝癌介入诊疗中的应用进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(03): 256-260.
阅读次数
全文


摘要